Space Peptides successfully completes the GMP inspection carried out by China’s regulatory agency National Medical Products Administration (NMPA, previously called CFDA). The comprehensive inspection covered the Space Peptides Xiamen facility’s quality processes and entire production system., which meets the requirements for producing peptide intermediates / advanced intermediates and active pharmaceutical ingredients (APIs) for clinical trial phase I and II. Currently, a pipeline of peptide therapeutic products with GMP / GMP-like standards are being manufactured at the site.
This demonstrates the company’s premier quality system in full compliance with regulatory requirements.
Dr. Runze He, CEO of Space Peptides, commented, “We are excited to successfully complete the regulatory inspection. We will continue to be dedicated to the highest quality standards and, ultimately, patient safety”